Bayer

Bayer Faces Make-or-Break Court Ruling as FDA Fast Tracks Two Drugs and Cash Burn Deepens

kashif hafeez - May 21, 2026

Bayer’s Q1 Smashes Forecasts as Crop Science Rebounds, But Glyphosate Cloud Remains

angelina - May 12, 2026

Bayer’s Legal Tightrope: Supreme Court Showdown Meets a €7 Billion Capital Cushion

April 26, 2026

Bayer’s Dividend Stays at Minimum as Supreme Court Glyphosate Hearing Looms

angelina - April 25, 2026

Bayer Faces a Week of Reckoning as Supreme Court, Shareholders, and Lobbying Scrutiny Converge

April 24, 2026

Bayer’s Clinical Pipeline and Factory Innovation Face Off Against a Mountain of Debt

angelina - April 23, 2026

Bayer’s Legal and Financial Tightrope Walk Enters Critical Phase

April 22, 2026

Bayer’s Stroke Drug Breakthrough Validates Turnaround Strategy

Brett Shapiro - April 17, 2026

Bayer’s Pivotal Quarter: Legal Battles and Leadership Shifts Shape the Path Forward

Brett Shapiro - April 11, 2026

Trade Tensions Cast Shadow Over Bayer’s Pharmaceutical Ambitions

kashif hafeez - April 6, 2026

FDA Approval of Lynkuet Marks Strategic Milestone for Bayer

Brett Shapiro - March 29, 2026

Analysts Shift to Bullish Stance on Bayer Shares

March 17, 2026

Bayer’s Oncology Ambitions: Darolutamid Study Targets Earlier Prostate Cancer Treatment

March 9, 2026

Bayer’s Financial Outlook Dimmed by Legal Liabilities

angelina - March 5, 2026

Legal Delays Threaten Bayer’s Settlement Strategy

kashif hafeez - February 28, 2026